Get the Stockscreener App
3.13
1.88%
-0.06
Wave Life Sciences Ltd stock is traded at $3.13, with a volume of 3.28M.
It is down -1.88% in the last 24 hours and down -30.52% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$3.19
Open:
$3.24
24h Volume:
3.28M
Relative Volume:
1.08
Market Cap:
$616.76M
Revenue:
$71.80M
Net Income/Loss:
$-183.59M
P/E Ratio:
-2.9688
EPS:
-1.0543
Net Cash Flow:
$-186.52M
1W Performance:
-9.54%
1M Performance:
-30.52%
6M Performance:
-57.24%
1Y Performance:
-60.23%
1-Day Range:
$3.08
$3.28
1-Week Range:
$3.0399
$3.46
52-Week Range:
$3.0399
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
3.13 | 616.76M | 71.80M | -183.59M | -186.52M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-26 | Initiated | UBS | Buy |
| Oct-01-26 | Initiated | Ladenburg Thalmann | Buy |
| Sep-23-26 | Resumed | JP Morgan | Neutral |
| Apr-29-26 | Resumed | Truist | Buy |
| Feb-05-26 | Initiated | BofA Securities | Buy |
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Form 4 Wave Life Sciences For: 10 October By Investing.com - Investing.com South Africa
Form 4 Wave Life Sciences For: 7 October By Investing.com - Investing.com Nigeria
Wave Life Sciences Director Christian Henry Awarded 10,700 RSUs and 64,000 Stock Options - Kalkine Media
A director receives a 10,700-share stock grant plus options at Wave Life Sciences (WVE). - Stock Titan
A director receives a 10,700-share stock grant and 64,000-share option at Wave Life Sciences (WVE). - Stock Titan
A director receives 10,700 stock units and a 64,000-share option at Wave Life Sciences (WVE). - Stock Titan
A 10,700-share stock grant joins 64,000 options for Wave Life Sciences (WVE) director Ken Takanashi. - Stock Titan
Wave Life Sciences Director Adrian Rawcliffe Awarded 10,700 RSUs and 64,000 Stock Options in 2026 Equity Grants - Kalkine Media
How Is GSK (LSE:GSK) Stock Reacting This Week To Its Wave Life Sciences Liver Candidate? - Kalkine Media
FDA supports a one-year data check for possible faster approval of Wave's treatment. - Stock Titan
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - TradingView
Wave Life Sciences stock hits a 52-week low at USD 4.20 - AD HOC NEWS
Wave Life Sciences Names Monika Vnuk Chief Business Officer - citybiz
Wave Life Sciences appoints Monika Vnuk as chief business officer By Investing.com - Investing.com Australia
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - The Manila Times
Wave Life Sciences Appoints Monika Vnuk as Chief Business Officer - Quiver Quantitative
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - Yahoo Finance
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com Nigeria
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com Canada
Wave Life Sciences at Cantor conference: RNA editing gains traction - investing.com
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com UK
Wave Life Sciences stock holds steady ahead of Cantor healthcare conference appearance - ad-hoc-news.de
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference - GlobeNewswire
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference - Yahoo Finance
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Wave Life Sciences stock trades quietly as investors focus on recent clinical progress - ad-hoc-news.de
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold" - MarketBeat
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - Simply Wall Street
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - simplywall.st
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - simplywall.st
Wave Life Sciences targets fat loss without sacrificing muscle - Longevity.Technology
Insiders Sold Wave Life Sciences Prematurely At US$13.64 With Stock Trading Higher - Moomoo
Wave Life Sciences (WVE) Pulls Back 5.2% to $5.13 as Support Holds at $4.87Thematic ETF Flow - vinanet.vn
Wave Life Sciences Ltd. SEC Filing (Aug 17, 2026) - Stock Titan
Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones - Stock Traders Daily
Wave Life Sciences, Inc.: Top Mutual Funds Holders | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Target Price Consensus and Analysts Recommendations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Performance & Quotes, WVE Stock Price on Nasdaq Exchange - marketscreener.com
Wave Life Sciences, Inc.: Fundamental Analysis and Financial Ratings | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Financial Data Forecasts Estimates and Expectations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc. Stock (WVE)Quote Nasdaq - marketscreener.com
Q1 2025 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
WAVE Life Sciences Ltd at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Q2 2026 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
Wave Life Sciences Ltd.: Revenue and Earnings Analysts Forecasts Revisions | WVE | US94352A1043 - marketscreener.com
WVE Q2 2026 Earnings: Wider-than-Expected Loss of $0.34 per Share Highlights Pipeline InvestmentProfit Growth Outlook - https://www.dars.gov.et/
Wave Life Sciences (WVE) Director Adrian Rawcliffe Sells 12,700 Shares, Reducing Stake to Zero - GuruFocus
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Wave Life Sciences Ltd Stock (WVE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rawcliffe Adrian | Director |
Aug 12 '26 |
Sale |
5.29 |
12,700 |
67,183 |
0 |
| ADRIAN G RAWCLIFFE | Director |
Aug 12 '26 |
Proposed Sale |
5.04 |
12,700 |
64,072 |
0 |
| TAKANASHI KEN | Director |
Aug 11 '26 |
Sale |
6.01 |
3,864 |
23,223 |
20,079 |
| Tan Aik Na | Director |
Aug 11 '26 |
Sale |
6.01 |
432 |
2,596 |
24,968 |
| HEIDI L WAGNER | Director |
Aug 11 '26 |
Proposed Sale |
6.07 |
7,000 |
42,490 |
0 |
| Wagner Heidi L | Director |
Aug 11 '26 |
Sale |
6.01 |
7,000 |
42,070 |
44,930 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 30 '26 |
Buy |
6.50 |
971,091 |
6,312,092 |
26,975,505 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '26 |
Buy |
6.43 |
2,495,623 |
16,046,856 |
26,004,414 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 26 '26 |
Buy |
6.08 |
5,305,782 |
32,265,431 |
23,508,791 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Option Exercise |
4.28 |
33,194 |
141,920 |
79,767 |
1.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):